Journal
METABOLITES
Volume 12, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/metabo12020186
Keywords
metabolomics; pharmaceutical active compounds; aquatic organisms; mechanism of action; biomarkers; multi-omics; hazard assessment; biomonitoring
Categories
Funding
- ANSES French National Research Program for Environmental and Occupational Health [ANSES-21-EST-072]
- Sanofi France
Ask authors/readers for more resources
This article discusses the current state and challenges of using environmental metabolomics to address ecotoxicological issues. The authors highlight the potential of this approach in elucidating contaminant mechanisms of action and developing biomarkers, particularly when combined with other omics approaches. The importance of linking molecular effects to adverse outcomes and the construction of adverse outcome pathways is also emphasized. The article concludes with recommendations to fully harness the advantages of environmental metabolomics.
Scientists often set ambitious targets using environmental metabolomics to address challenging ecotoxicological issues. This promising approach has a high potential to elucidate the mechanisms of action (MeOAs) of contaminants (in hazard assessments) and to develop biomarkers (in environmental biomonitoring). However, metabolomics fingerprints often involve a complex mixture of molecular effects that are hard to link to a specific MeOA (if detected in the analytical conditions used). Given these promises and limitations, here we propose an updated review on the achievements of this approach. Metabolomics-based studies conducted on the effects of pharmaceutical active compounds in aquatic organisms provide a relevant means to review the achievements of this approach, as prior knowledge about the MeOA of these molecules could help overcome some shortcomings. This review highlighted that current metabolomics advances have enabled more accurate MeOA assessment, especially when combined with other omics approaches. The combination of metabolomics with other measured biological endpoints has also turned out to be an efficient way to link molecular effects to (sub)-individual adverse outcomes, thereby paving the way to the construction of adverse outcome pathways (AOPs). Here, we also discuss the importance of determining MeOA as a key strategy in the identification of MeOA-specific biomarkers for biomonitoring. We have put forward some recommendations to take full advantage of environmental metabolomics and thus help fulfil these promises.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available